TrialBlood cancer journal2021

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.

Stefania Oliva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.